When was Myrtelle founded?

Myrtelle was founded in 2021 and raised its 1st funding round 3 years after it was founded.

Where is Myrtelle located?

Myrtelle is headquartered in Wakefield, United States.

How many employees does Myrtelle have?

As of Jun 30, 2026, the latest employee count at Myrtelle is 11.

Is Myrtelle a funded company?

Myrtelle is a funded company, having raised a total of $77.2M across 5 funding rounds to date. The company's 1st funding round was a $***** Conventional Debt round, raised on May 21, 2024.

When was the latest funding round of Myrtelle?

Myrtelle's latest funding was a $***** Series C round on Jul 23, 2026, with participation from 0 investor. Its primary sector is Gene Therapy. In United States, the Gene Therapy sector has seen $1.01B in funding in 2026 to date.

Where does Myrtelle rank among its competitors?

Myrtelle ranks 27th amongst 138 active competitors, of which 49 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Myrtelle, which secured $30M in Jul, 2026.

Who are the top competitors of Myrtelle?

Myrtelle's top competitors include Senti Bio, Bluebird Bio and Tenaya Therapeutics. Among them, Myrtelle secured the most recent funding round in July, 2026.

Myrtelle - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of gene therapies for the treatment of neurological diseases. The company's lead program is a novel investigational gene therapy treatment for Canavan disease. It is developing a vector, called rAAV-Olig001-ASPA to deliver a therapeutic ASPA gene directly to the oligodendrocyte cells that are responsible for producing myelin to restore the ability of oligodendrocytes to make the ASPA enzyme on their own.

Website: myrtellegtx.com
Email ID: *****@myrtellegtx.com
Phone Number: +1 **********

Key Metrics

Founded Year

2021

Location

Wakefield, United States

Stage

Series C

Total Funding

$77.2M in 5 rounds

Latest Funding Round

Series C, Jul 23, 2026, $*****

Investors

Panacea Venture

Ranked

27^th among 138 active competitors

Employee Count

11 as on Jun 30, 2026

Similar Companies

Senti Bio & 157 more

View Myrtelle's full profile

Myrtelle is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
MYRTELLE, INC. CIN: 853809400 , United States, Active	Dec 31, 1999	-	9 (As on Dec 31, 2024)	-

Myrtelle has raised a total funding of $77.2M over 5 rounds. Its first funding round was on May 21, 2024. Myrtelle has 1 institutional investor.

Here is the list of recent funding rounds of Myrtelle:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 23, 2026	7814088	Series C	5533889	4238444	5528834	9021204
Jun 22, 2026	7745770	Series C	4189169	6025107	5879029	7513073
Dec 11, 2025	1416135	Series C	2693291	8740905	5069448	6969046

Access funding benchmarks and valuations. Sign up today!

View details of Myrtelle's funding rounds and investors

Myrtelle's employee count trend

Myrtelle has 11 employees as of Jun 26. Here is Myrtelle's employee count trend over the years:

Uncover Myrtelle's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Myrtelle include Senti Bio, Bluebird Bio and Tenaya Therapeutics. Here is the list of Top 10 competitors of Myrtelle, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
2nd	Bluebird Bio 1992, Cambridge (United States), Acquired	Developer of gene therapies for severe genetic and rare diseases	$136M	TVM Capital, Forbion & 10 others	71/100
3rd	Tenaya Therapeutics 2016, San Francisco (United States), Public	Developer of regenerative and gene therapeutics for heart failure	$248M	RA Capital Management, Fidelity Investments ... & 7 others	70/100
4th	Passage Bio 2017, Philadelphia (United States), Public	Developer of gene therapies for CNS rare diseases	$226M	Access Biotechnology, Orbimed & 10 others	69/100
5th	ImmunoACT 2018, Mumbai (India), Series B	Developer of cell and gene therapies for cancer treatment	$15.9M	SINE, Laurus Labs & 4 others	67/100
6th	Harmony Biosciences 2017, Plymouth Meeting (United States), Public	Developer of therapeutics for rare neurological diseases	$345M	Fidelity Investments, VenBio & 12 others	66/100
7th	Mammoth 2017, Brisbane (United States), Series D	Provider of molecular diagnostics platform by using CRISPR technology	$271M	Redmile Group, Decheng Capital & 34 others	65/100
8th	Evox Therapeutics 2016, Oxford (United Kingdom), Series C	Developer of exosome-based therapeutics for severe neurological and rare diseases	$156M	Redmile Group, Gates & 26 others	64/100
9th	QurAlis 2016, Cambridge (United States), Series B	Developing drugs & CSF cartridge device for treating amyotrophic lateral sclerosis (ALS)	$155M	Amgen Business Development, Acks & 21 others	63/100
10th	Nuevocor 2021, Singapore (Singapore), Series B	Developer of genetic medicines for treating rare heart muscle conditions	$80.6M	Boehringer Ingelheim Venture Fund, Angelini Ventures ... & 7 others	62/100
27th	Myrtelle 2021, Wakefield (United States), Series C	Developer of gene therapies for the treatment of neurological diseases	$77.2M	Panacea Venture	49/100